Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06029660




Registration number
NCT06029660
Ethics application status
Date submitted
1/09/2023
Date registered
8/09/2023
Date last updated
29/05/2024

Titles & IDs
Public title
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
Scientific title
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
Secondary ID [1] 0 0
CRD 1029
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Aortic Aneurysm, Abdominal 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - IMPEDE-FX RapidFill Implants
Treatment: Surgery - EndoVascular Aneurysm Repair

Experimental: Treatment - Treatment Arm: Subjects in the treatment arm will have both an EVAR device and IMPEDE-FX RapidFill implants inserted.

Active Comparator: Control - Control Arm: Subjects in the control arm will only have an EVAR device implanted.


Treatment: Devices: IMPEDE-FX RapidFill Implants
Filling of the available flow lumen within the AAA sac with IMPEDE-FX RapidFill Implants

Treatment: Surgery: EndoVascular Aneurysm Repair
Standard EVAR repair of abdominal aortic aneurysms using a commercially available stent.
Intervention code [1] 0 0
Treatment: Devices
Intervention code [2] 0 0
Treatment: Surgery
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Primary Effectiveness Endpoint : AAA Sac Regression at 1 year
Timepoint [1] 0 0
1 year
Primary outcome [2] 0 0
Primary Safety Endpoint : Major Adverse Event (MAE) Rate through 30 days
Timepoint [2] 0 0
30 days

Eligibility
Key inclusion criteria
1. =18 years of age

2. A candidate for elective EVAR of an infrarenal fusiform aortic aneurysm =5.5 cm in
diameter in men and =5.0 cm in women;

3. Thrombus burden (percentage of the AAA sac occupied by thrombus) <50%, based on
pre-procedure CTA

4. Maximum Lumen diameter within the AAA sac of =40mm.

5. The predicted minimum number of IMPEDE-FX RapidFill Implants for the subject is =200.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
General

1. An inability to provide informed consent.

2. Enrolled in another clinical study that could interfere with the outcomes being
studied in this trial.

3. Unable or unwilling to comply with study follow-up requirements.

4. Prisoner or member of other vulnerable population

Anatomical

1. Concomitant iliac artery ectasia or aneurysm

2. Vascular disease and/or anatomy that preclude the safe access and positioning of a
catheter to deliver the investigational product into the AAA sac.

3. Ruptured, leaking, inflammatory or mycotic (infected) aneurysm.

4. Connective tissue disorder (e.g., Marfan's syndrome)

5. Aneurysmal disease of the descending thoracic aorta

6. Excessive calcification at the aortic bifurcation to common/internal iliac
bifurcation, that might lead to access difficulties

EVAR/Procedural

1. Use of aortic stent grafts other than the Gore Excluder AAA Endoprosthesis, Gore
Excluder Conformable AAA Endoprosthesis, Cook Zenith Flex AAA Endovascular Graft,
Medtronic Endurant II and Endurant IIs Stent Graft, or the Terumo TREO Stent Graft to
treat the AAA

2. Use of an aortic stent graft other than those specified1 for a particular site

3. Planned use of the chosen stent graft outside its instructions for use (IFU)

4. Use of fenestrated stent grafts or chimney techniques

5. Use of the Heli-FX EndoAnchor system

6. Use of embolic devices other than the investigational product to embolize the AAA sac

7. Use of embolic products to prophylactically or concomitantly embolize the inferior
mesenteric artery, lumbar arteries, renal accessory arteries, or internal iliac
arteries

8. Inability to land the distal-most portion of the EVAR stent graft limbs, including
extensions, above the internal iliac arteries

Medical History/Conditions

1. Coagulopathy or uncontrolled bleeding disorder

2. Serum creatinine level >2.5 mg/dL

3. Cerebrovascular accident within 3 months prior to the procedure

4. Myocardial infarction and/or major heart surgery within 3 months prior to the
procedure

5. Atrial fibrillation that is not well rate controlled

6. Life expectancy of <2 years post-procedure

7. Known hypersensitivity or contraindication to platinum, iridium, or polyurethane.

8. Have active infection at the time of the index procedure documented by pain, fever,
drainage, positive culture, or leukocytosis (WBC >11,000/mm3)

9. A condition that inhibits radiographic visualization during the implantation procedure

10. History of allergy to contrast medium that cannot be managed medically, or subject is
unable to have a CT with contrast for any reason.

11. Uncontrolled co-morbid medical condition, including mental health issues, that would
adversely affect participation in the trial

12. Pregnant or lactating female: for females of child-bearing potential, based on a
positive pregnancy test within 7 days prior to the procedure or refusal to use a
medically accepted method of birth control for the duration of the trial

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/04/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2030
Actual
Sample size
Target
180
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Indiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Ohio
Country [7] 0 0
United States of America
State/province [7] 0 0
Pennsylvania
Country [8] 0 0
United States of America
State/province [8] 0 0
Virginia
Country [9] 0 0
Netherlands
State/province [9] 0 0
Gelderland
Country [10] 0 0
Netherlands
State/province [10] 0 0
Tilburg
Country [11] 0 0
New Zealand
State/province [11] 0 0
Auckland

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Shape Memory Medical, Inc.
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
NAMSA
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage
of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to
on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects
considered candidates for elective EVAR.
Trial website
https://clinicaltrials.gov/ct2/show/NCT06029660
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Marc Schermerhorn, M.D.
Address 0 0
Beth Israel Deaconess Medical Center
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Irene Kuhn
Address 0 0
Country 0 0
Phone 0 0
646-369-1591
Fax 0 0
Email 0 0
ikuhn@namsa.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06029660